Crops Would Eclipse Drugs at Bayer After Monsanto Deal: ChartBy
The balance seems to be shifting at Bayer AG. By buying Monsanto Co., the German company would see its crop-science unit surpass pharmaceuticals in sales. The health-care business generated about 44 percent of sales last year, more than any other Bayer division.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.